



Emerging Immunomodulation Technologies May Potential Improve the Clinical and Pharmaceutical Health Care

Taha Nazir¹, Saeed Ur Rashid Nazir^{2*}, Misbah Sultana⁴, Humayun Riaz⁵, Muhammad Naeem Qaisar², Nida Taha¹, Muhammad Amer⁶, Azharul Islam³

1. Microbiology, Chemical Pathology and Molecular Biology Research Group, Advanced Multiple Inc., Mississauga ON Canada.
2. Faculty of Pharmacy, College of Pharmacy, University of Sargodha, Sargodha 40100, Pakistan.
3. Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555, USA
4. University College of Pharmacy, University of the Punjab, Lahore, Pakistan.
5. Rashid Latif College of Pharmacy, Lahore, Pakistan.
6. Department of Pharmacy, The University of Lahore, Islamabad Campus-Islamabad, Pakistan.

*Corresponding author's E-mail: srnazir@yahoo.com

Received: 16-04-2020; Revised: 22-06-2020; Accepted: 30-06-2020.

ABSTRACT

The innovative immunomodulation technologies are excellent tools to synthesis the novel antibodies. The conventional methods are potentially replaced by more précised techniques to obtain the desired antibodies. Particularly the hybridoma technique used to produce the antibodies against targeted antigens. The pathogenic microorganisms, autoimmune agents and other malignant entities can be controlled by using these innovative immunomodules. Moreover, the abundant powerful toxic substances can be handled with such monoclonal antibodies. These analytical acculturated or chimeric murine antibodies have a couple of imperatives and complexities. In order to vanquish these problems, late advancements in inherited building procedures and phage indicate framework have conceded the making of exceedingly recombinant antibodies that are specific. Moreover, highly specified recombinant antibodies are produced by the recent advancements in genetic engineering procedures and phage display procedure. The antibodies chase for novel remedial medications outfitted with upgraded immune protective capacities such as drawing in invulnerable effector capacities, viable advancement of combination proteins, productive tumor tissue infiltration and high-partiality antibodies coordinated against targets. Propelled neutralizer building systems have broad practices in the fields of diagnostics, biotechnology, immunology, and helpful prescriptions. Notwithstanding, there is restricted information with respect to dynamic neutralizer advancement approaches. Consequently, our ability to comprehend the customary polyclonal and monoclonal antibodies and advanced immunizer designing strategies has widened the clinical use imaginative counter acting agents.

Keywords: Immunomodulation, Antibody-dependent cell-mediated cytotoxicity, Monoclonal antibodies, Polyclonal antibodies, Heathier future.

INTRODUCTION

The IgG sub-class antibodies are bi-practical atoms, having F(ab) space, variable in arrangement and in charge of the official of antigen, and a Fc area, steady in succession and in charge of interceding a scope of neutralizer effector capacities.¹ These capacities are basically activated through connection with the

supplement segment C1q or with a group of FcγRs communicated, fundamentally, on the outer most layer of leukocytes. Every IgG isotype has an alternate restricting profile to the different FcγRs, and each FcγR has an alternate cell expression design. These distinctions empower the broadness, adaptability and control of capacity required to mount a compelling and controlled humoral reaction.





Figure 1: The structure, functions and activities of variable and constant regions of Ab.

Demolition of Tumor Cells

In spite of the fact many portion of the monoclonal antibodies (mAbs) utilized now a days may actuate immune mediated demolition of tumor cells,²⁻⁴ mAbs focusing on immunomodulatory particles to upgrade antitumor insusceptibility may speak to the following significant advancement in growth treatment. In fact, a few techniques as of now in presence give verification of-idea that remedially re-instructing T cells to instigate an antitumor insusceptible reaction might be gainful, including assenting T-cell therapy and growth vaccines.^{5,6} The patients who accomplished clinical advantage with these methodologies give prove that refocusing the resistant framework to treat malignancy is conceivable. Mounting proof has demonstrated that patients with growth can have safe reactions to malignancy.⁷⁻⁹ Moreover, the nearness of T cells has been appeared to be prescient of enhanced clinical outcome.¹⁰

The Antigen Presenting Cells (APC) promote the differentiation in effector CD8 T-cell activated by the CD40 agonist antibody. The agonist antibody, with ligation of CD137 (4-1BB), raise the costimulatory signals. Along with the increase in costimulatory signals, the clogging of PD-1 with an antagonist antibody happened that lowers the level of coinhibitory signals. The mutual response of these antibodies may accelerate the action and continuity of effector CD8 T cells at tumor sites (Figure 2). The antibody named anti-CTLA-4 results the clogging the signals of CTLA-4 or depletion of CTLA-4 + CD4 Tregs. The effector CD8 T cells are liberated from the immunosuppression mediated over Tregs in the result. At the end, the anti-CD19 antibody is reduced CD19+ Bregs. The shift from a protumor Th2 cell is boosted to an antitumor Th1 cell to produce antitumor effector CD4 T cells. As a whole, the set of immunomodulatory antibodies which are capable to target both stimulatory and regulatory structures, if taken in aggregate form could direct to a long-term shielding antitumor immunity (Figure 2).



Adopted from: American Association for cancer research ©2014 CCR Translations AACR.

Figure 2: Mechanisms immunomodulatory antibodies delivery in cancer treatment.




Figure 3: Inhibition of inhibitory receptor by antibodies to activates the NK cell.

The expansive size of mAbs points of confinement tumor infiltration, and their long half-life of tissue fluid is not reasonable for treatment and operations used for obtaining their pictures. In this manner, counter acting agent sections have been developed in different arrangements as they are little, containing only one kind of antibody, infiltrate tumor cell network proficiently, and are quickly wiped out by nephritic freedom.¹¹

So also, recombinant antibodies have a few points of interest: (i) microscopic organisms, plants, yeast, or


creatures can be utilized to deliver antibodies, (ii) no requirement for inoculation, and (iii) inherent characteristics (immunity resistance, restricting partiality, mode of action, specificity, and security of antibodies) could be adjusted effectively utilizing mutation causing procedures. Hereditarily built antibodies have fundamental attributes that proceed different succeeding applications or could be changed over into utilitarian entire immunoglobulins.¹² Antibodies show solid insusceptibility to protect against outside antigens and non-self-specialists. Be that as it may, an assortment of recombinant antibodies is expected to associate these antagonistic antigens. In the course of the most recent decade, the utilization of counter acting agent designing or recombinant immune response innovation has molded the hereditary control of a different scope of immunizer pieces for research, conclusion, and treatment (Figure 2).¹³ This innovation has brought about better partiality and specificity of controlled immune response pieces and has encouraged the supplanting of hybridoma innovation with different show frameworks for boundless counter acting agent creation against any known antigen.

On the other hand, designed antibodies have different disservices, for example, they show more prominent cost and unpredictability in assembling contrasted with antibodies created by hybridoma innovation.¹⁴ Because of their remote nature, built remedial antibodies prompt allotypic invulnerable reactions that outcomes in quick freedom from the body by kidney, inspire from the help of T-cell, and have decreased counter acting agent eagerness. Also, built antibodies show decreased half-life because of absence of a Fc space and aversion of FcRn-interceded reusing. In like manner, immune response-based treatments have more restrictions in light of the way that many targets (once in a while in low level) have not yet been resolved for different maladies.^{11,15,}

Engineered Immunomodulatory Antibodies

The procedures which modifies the immune response are perseveringly advancing to extend the clinical adequacy of helpful antibodies. Antigens which are present on the surface of cells display a wide exhibit of focuses on that are overexpressed, changed or specifically communicated, and chosen for balanced immune response-based therapeutics. The innovation capacities through designing changes in antigen or receptor work, the safe framework i.e., modifying Fc capacity and T cell actuation and

counteracting agent adjoined medication conveyance framework (DDS) focusing on a particular antigen. Antibodies which modifies immune response have increased huge clinical achievement.¹⁶



Adopted from: Insight Pharma Reports

Figure 4: Genetic engineering of mouse hybridoma, transgenic mouse human hybridoma and V gene cloning Complementary Determining Region (CDR) grafting eukaryotic expression.




Figure 5: Seven novel approaches used to take the advantage of innovative potential and construct mAb component by incorporating the new entities to hit the target, modify the host response or retarget the cellular immunity.

The place where Fc antibody is present, is regulated by designing the effector work, for instance to increment or reduce official to Fc gamma receptors (FcγRs) or supplement components and half-existence of IgG. By enhancing proclivity of Fc for Fc neonatal receptor (FcRn), the half-life could be reached out. Besides, it can be drawn out by designing pH-subordinate antigen authoritative to improve reusing of IgG by means of FcRn, and successful official to the objective particle. Designing the Fc area allows the advancement of particles that are more qualified to the pharmacology movement required of them.^{17,18} As of late, a review examines building the pH-subordinate cooperation amongst IgG and FcRn. It includes regulation of consistent Fc some portion of identical cells human antibodies IgG1 (hIgG1) to enhance effector capacities and

analytical adequacy of cutting edge IgG1-based remedial treatments.¹⁹

So also, new open doors have been made by the improvement of neutralizer medication adjoins (ADCs) to cure the irresistible illnesses or spot the malignancy cells. ADCs are being produced by advancing in immune response era, choice of over pacing toxic atoms for cells, and development of balanced adjoiners that can be examined in clinical trials.¹⁷ Cytotoxic restorative mAbs frequently help the target cell-slaughtering by evoking resistant effector capacities. These incorporate immunizer subordinate cell-interceded cytotoxicity (ADCC), neutralizer subordinate cell phagocytosis (ADCP) intervened by inborn insusceptible effector cells, and supplement subordinate cytotoxicity

(CDC) interceded by humoral segments (Figure 6). *in vitro* considers, Fc building strategies have been particularly intended to adjust ADCP, CDC and ADCC imagined for helpful intervention.²⁰

Characteristic executioner Natural killer cells show basic part in invulnerability with regards to mAb therapy by applying direct cytotoxicity towards contaminated or tumor cells and contribute in demonstrating the versatile reaction.²¹ A few T-or NK-cell regulators, for example, nivolumab and ipilimumab have been endorsed for the therapy of metastatic melanoma.²²

Fc-designed antibodies enhance the ADCP/ADCC potential and Her2, CD19, CD20 and CD40 were targeted. Thusly, they upgrade the remedial capability of mAbs. The NK cells which are selective in showing low-liking actuating FcγRIIIa (CD16), and show no inhibitory immune response receptors, including a considerable part in ADCC. By utilizing the models of mouse tumor, a few reviews have built up a connection between initiating Fc receptors and the adequacy of mAb treatment.²³

As of late, glyco-designing strategy has been utilized to deliver recombinant helpful proteins with upgraded viability, specificity, antigenicity and half-life. Glyco-building of expression stages is logically reported as a basic way to deal with progress biopharmaceuticals.²⁴ For the creation of recombinant proteins a procedure has been connected to *in vivo* interpretation. This procedure incorporates mammalian cells, yeast, plants and creepy crawly cells for the formation of recombinant proteins. The highlighted ways go for characterized synthesis of glycoproteins with homogeneous O-and N-connected glycans.²⁴ In eukaryotic cells multi-level glycol-strategies have been used. These strategies are used to create characterized Fc-glycans with IgG.²⁵ Also, expression of *E. coli* has been effectively utilized to deliver recombinant human interleukin-2 (IL-2).

Bacterial, Ribosome and Yeast Display Techniques

Antibodies which are designed with unrivaled characteristics, for example, restricting fondness, security, and synergist action by a few other show instruments (for instance, bacterial and yeast show) for expansive range of biomedical applications, drug and biotechnology. Surface of yeast show advancement of recombinant antibodies by showing on the *Saccharomyces cerevisiae* superficial layer by means of hereditary combination to an inexhaustible cell divider protein.²⁶

Yeast show system has been utilized for designing protein partiality, steadiness, and enzymatic action. Also, it is widely connected in the mapping of protein epitope, distinguishing proof of protein to protein co-operations, and employments of showed proteins in medication and industry.²⁷ For the show of deadly contaminations by yeast, some recombinant antibodies have been formed, for example, very pathogenic H5N1 avian flu infection, cell tumor and tumor of human endothelial marker 1 (TEM1).²⁷⁻²⁹

Essentially, a few bacterial show frameworks have been built up for Gram-negative microscopic organisms and Gram-positive microbes. The show frameworks included a transporter protein as a tying down theme, a host strain and objective protein. Proteins produced for utilization as securing themes incorporate external film proteins, subunits of surface extremities, lipoproteins, S-layer proteins and autotransporters.³⁰ The applications for broad bacterial show include live antibody improvement, screening-showed biosorbents, biosensor advancement, entire cell biocatalysts and peptide libraries. Additionally, the promising innovation is aiding in the remediation of toxins, biofuel generation, and creation of enantiomerically immaculate mixes.^{30,31}

Ribosome show cell display framework, and a method to function altogether *in vitro* choice of peptides or proteins to tie coveted ligand. Ribosome show comprises of both eukaryotic and prokaryotic show frameworks. It frames balance protein-ribosome-mRNA (PRM) buildings and connections particular early proteins (phenotypes) to their practically equivalent to detachment RNA (mRNA) (genotypes). Ribosome show the encoding of mRNA and permits the integrated segregation of a utilitarian incipient protein through the proclivity for a ligand. After that the encoding of mRNA is changed and opened up as DNA for extra control, including rehashed period or protein expressions. The upsides of ribosome show by other cell-based techniques incorporate showing expansive libraries, producing poisonous, proteolytically touchy and shaky proteins, and consolidation of changed amino acids or transformations at unmistakable locations. Ribosome show frameworks have been explored to recognize potential antigens of *Clonorchis sinensis*, and human tumor corruption consider α (hTNF α) for finding and therapy.^{32,33}

Utilizations of Antibodies

Von Behring and Kitasato in 1890's taken a shot at lockjaw neutralizing agent that prompt the improvement of another train, immunology. They portrayed antibodies interestingly and found that latent poisons can evoke a defensive safe reaction against dynamic poisons in creatures. The transfusion of serum from these ensured creatures inspired an invulnerable reaction in different creatures. Subsequently, antibodies were initially known as "counteragents." Since then, antibodies have been appeared to have a more extensive collection of antigen acknowledgment. Antibodies are generally utilized as a part of symptomatic tests alluded as "immunoassays." These are utilized to affirm analyze and for quickly developing immunizer-based innovations.³⁴

Antibodies have significant functions in the field of therapeutics, diagnostics and focused on DDS. Antibodies have been utilized to concentrate different sicknesses, for example, disease, metabolic and hormonal scatters, and contaminations brought about by microorganisms, infections, growths, green growth, protozoa and different operators.³⁵ Besides, these biomolecules have various applications in the analysis of myeloid and lymphoid



malignancies. In like manner, immunoglobins were utilized as a part of tissue writing, serotyping of microorganisms, radio immunoassay, ELISA, immunological intercession with latent neutralizer, breaking down a patient's counter acting agent profile, and antibodytype hindrance.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA is the most widely recognized strategy for the calculation of neurotic antigens. Now and again, adjusted ELISA have been utilized as a part of blend with different particular proteins/peptides. It is fast, predictable, moderately simple to investigate, and versatile to high-throughput screening.³⁶

Essentially, particular counter acting agent is inactive on high restricting ELISA plates by brooding at 4°C for overnight or at 37°C for 1-2 hours, and afterward taken after by 3–5 rinses with PBST (8.1 mM Na₂HPO₄, 2.7 mM KCl, 137 mM NaCl, 0.5% Tween 20 and 1.5 mM KH₂PO₄). At that point, plates are hindered with unessential protein e.g., egg whites (for instance, PBS containing 4–5% separated drain), and brood at 4°C for overnight or at 37°C for 1–2 h. After rinses, tests and standard weakening are poured to the wells to be caught by conjugated protein, brood for 1–2 h at 37°C and rinse legitimately. Next, particular peroxidase-conjugated compound marked recognition neutralizer is added to the wells to empower identification of the caught protein and hatch at 37°C for 1h. After fitting rinse, colorimetric substrate is poured to the wells and brooded at 37°C for 15-20 min for the shading improvement as activated by the chemical. For example, expansion of 3,3',5,5'-tetramethylbenzidine (TMB) substrate creates blue shading that is analyzed by microplate plate peruser at the wavelength of 562 nm. Also, expansion of 0.16–2 M sulfuric corrosive (H₂SO₄) as a pause response arrangement creates yellow shading that can be perused at 405–450 nm respectively. Moreover, the reagent definitions and the hatching conditions ought to be ideally advanced in view of the sort of ELISA.^{37,38}

There are four ELISA strategies. Coordinate ELISA (dELISA) utilizes rivalry between undesirable proteins for plastic restricting spots. Antigen is joined to the strong stage taken after by a protein named immune response. This examine is utilized to identify different pathogenic antigens.³⁹

Circuitous ELISA (iELISA) utilizes an antigen joined to a strong stage taken after by the expansion of unlabeled essential immunizer. Rather, a peroxidase chemical conjugated auxiliary neutralizer is included onto the main immunizer. The iELISA is utilized to recognize particular antibodies in sera.⁴⁰

Focused ELISA (cELISA) is utilized for the discovery of little particles without numerous epitopes. Particular antibodies to the analyte of intrigue are inactive on a small-scale titer plate. At that point, catalyst conjugated antigen is hatched with catch immunizer and a similar antigen in its unassociated frame. This progression results shading taking after the expansion of substrate. The signs created are specifically corresponding to the amount of adjoined

chemical bound and conversely relative to the amount of unassociated antigen exhibit.⁴¹

Sandwich ELISA (sELISA) is utilized for bigger proteins with two antibodies and different epitopes can be utilized continuously. The catch immune response is inactive on a microtiter plate. At that point, obscure or called specimens are added into the lattice to limit connection to the strong stage. Peroxidase-compound marked neutralizer is then included for hue, which is specifically corresponding to the measure of antigen present.⁴²

ELISA has been broadly utilized as a part of the location of different neurotic antigens from viral, contagious, protozoa, bacterial, algal, and various different origins. An enhanced ELISA has been utilized for distinguishing hostile to melanoma separation related quality antibodies 5 (MDA5) that are communicated in patients of dermatomyositis. Clinical investigation of this recently created ELISA displayed proficient recognition of against antibodies MDA5 and demonstrated assuring potential to help the routine clinical evaluation of hostile to antibodies MDA5 in patients with possibility to have DM.⁴³

Immunoblotting

Western blotch test (WBA) is likewise known as immunoblotting. The strategy of immunoblotting is utilized for the assurance of sub-atomic weight and measure of significant proteins introduce in a specimen. Proteins in an example are first isolated by electrophoresis and afterward exchanged to a polyvinylidene difluoride (PVDF) or nitrocellulose layer for the location of fixed essential proteins with antibodies particular to protein of intrigue.⁴⁴

Nonspecific locales in the film are then obstructed with BSA, casein or fat free drain powder. At long last, a named optional immune response is included for location by chemiluminescence or fluorescence.⁴⁵ WBA has been utilized for the affirmation of nearness of refined proteins delivered against different obsessive antigens, for example, the deadly poison of *Clostridium sordellii*,⁴⁶ shiga poison Stx2f,⁴⁷ *Staphylococcus aureus* alpha-hemolysin (alpha-poison), *Selenocosmia huwena* huwentoxin-IV (HWTX-IV) and *V. parahaemolyticus* thermolabile hemolysin (TLH).^{48,49}

Spot Blot

Spot Blot (DB) tests are utilized to quantify protein fixations semi-quantitatively. This is marginally not the same as the WBA. Proteins for example are not isolated by electrophoresis but rather are perceived straightforwardly on a film and hybridized with a neutralizer test.⁵⁰ This method is practical and utilizes avidin-biotin innovation with diaminobenzidine as a chromogen. It is utilized for the examination and calculation of 14-3-3 protein in cerebrospinal liquid (CSF) tests from instances of Creutzfeldt-Jakob infection (CJD), and for malady to overcome other neurodegenerative ailments, for example, Alzheimer's illness (AD) and Parkinson's sickness (PD).⁵¹



Immunohistochemistry

Immunohistochemistry (IHC) is utilized for the discovery and distinguishing proof of proteins and their limitation in tissues. It is basic to hold the tissues morphology, morphology of cells and the accessibility of antigen locales. New, quickly solidified tissue areas are ideally utilized for IHC by synthetically settling tissues in formalin and implanting in wax.⁵² Also, settling crosslinks amino acids in the tissue that square approach to the epitope destinations and keep the activity of any protein particular antibodies. The presentation of shrouded epitope districts is achieved by assimilation with a compound or by warmth therapy, which evacuates internal peroxidase movement and non-particular locales are clogged. A named counter acting agent or an unlabeled essential immune response particular to the protein of intrigue is utilized, trailed by the expansion of an auxiliary named neutralizer particular to the essential immunizer.⁵³

IHC has as of late been utilized for assurance and distinguishing proof of communicated proteins, for example, lysosome-related protein transmembrane-4 beta (LAPTM4B) related with the guess of a few human malignancies glucagon-like peptide-1 (GLP-1) against the damage of kidney tubes and CD147 trans-layer protein that initiates the movement of framework of metalloproteinases (MMP) and its expression.^{54,55}

Immunoprecipitation

Immunoprecipitation (IP) is utilized for the investigation of protein to protein collaborations, particular catalyst movement, posttranslational adjustments, protein measurement, and assurance of atomic weight of protein antigens. This procedure incorporates counter acting agent/antigen cleaning buildings at state that particularly tie antibodies. Proteins uncommonly, can be gathered up to 10,000-crease by IP. Luciferase immunoprecipitation framework (LIPS) has been produced for the quick identification of antibodies versus peste des petits ruminant's infection (PPRV),⁵⁶ varicella-zoster infection (VZV),⁵⁷ zinc transporter (ZnT8) autoantibodies,⁵⁸ duodenal and pancreatic homeobox 1 autoantibodies (PAA).⁵⁹

Enzyme Linked Immunospot

Protein connected immunospot (Elispot) examine is utilized for checking cell insusceptible reactions in people and different creatures. It includes a polyvinylidene difluoride (PVDF) helped microtiter plate pre-covered with antibodies particular to the antigen of intrigue. A catch neutralizer ties to the analyte of enthusiasm covered by exact state. At that point, a biotinylated counter acting agent particular to the analyte of intrigue is summed to distinguish the first immune response after washing to expel cellular trash. At long last, a catalyst named conjugate is added following a moment rinse to evacuate unattached immunizer and to envision a shaded item. The item is regularly a dark spot speaking to a solitary cell that creates the antigen of intrigue. This method was utilized as a part of the advancement of a coxsackievirus A16 balance test and the

assurance of rotavirus infectivity.⁶⁰ Analytic applications incorporate diagnosing refinement to house tidy parasites,⁶¹ pneumonic tuberculosis,⁶² pleural tuberculosis,⁶³ spread negative tuberculosis, spinal tuberculosis and cytomegalovirus disease.⁶⁴

Parallel Flow Test

The parallel stream immunochromatographic test (LFT) is a basic and savvy gadget used to distinguish the nearness or nonattendance of an objective antigen. It is broadly utilized for restorative diagnosis performed at home (pregnancy test) or in a research facility analysis. The innovation includes the conveyance of liquids (e.g., pee) through pieces of permeable paper, fine beds, sintered polymers or microstructured polymers.⁶⁵

The system involves different parts and steps. An example cushion goes about as a wipe and retains the liquids. At that point, liquids move to an adjoined cushion which contains conjugates of protein inactivated on the surface of bio-dynamic sugar particles and salt network that responds with the antigen. Next, specimen liquids break up the conjugate salt-sugar framework and counter acting agent particles. The liquid blend courses over the permeable framework creating the analyte to tie with molecules while moving further over the third slender surface. At last, there is a third catch atom in striped regions that ties to the liquid blend which contains analytes and the molecule thus shifts shading.⁶⁶ LFTs can be utilized as an aggressive or sandwich measure. Latex (blue shading), nanometer-sized particles of gold (red shading), or bright or attractive marked molecules are likewise utilized. The method is subjective, by and by, the amount of analyte substance in a specimen can be calculated by the power of the test line shading. It is typically done by optical and non-optical parallel stream per users or biosensors (LFBs, for example, a charge-coupled gadget (CCD) or integral metal-oxide semiconductor (CMOS) and attractive immunoassay (MIA).⁶⁷

Finding and Cure

Advance in hybridoma innovation and the generation of exceedingly particular mAbs has changed the remedial utilization of antibodies for the determination and treatment of contaminations, the improvement of immunizations, antigenic portrayal, and hereditary control. Antibodies have across the board operations in therapeutics, diagnostics and focused on DDS against, tumor, physiological issues and intense disease-causing microbes (Figure 2).⁶⁸

These applications are utilized for the determination of myeloid and lymphoid malignancies, tissue portrayal, ELISA, serotyping of organisms and radiolabeled immunoassay. What's more, they are utilized as a part of the determination of immunological insertion with inactive antibodies, against idiosyncrasy concealment, or enchantment slug medications with cytotoxic operators set to hostile to mouse particular antibodies. So also, recombinant DNA innovation (rDNA) has upset the recreation of mAbs by hereditary building utilizing chimeric antibodies, CDR joined



antibodies and acculturated antibodies for helpful utilization.⁶⁹

Imaging

Atomic imaging gives a touchy, non-intrusive strategy for the sub-atomic portrayal of the surface of the cell phenotype for illness finding and cure. It is a quickly developing multidiscipline that includes atomic science, pharmaceutical and immunology. The remedial uses of antibodies incorporate clinical determination and treatment in autoimmunity, hematology, immunology, cardiology, oncology and irresistible ailments.⁷⁰

MABs can be utilized as sub-atomic imaging tests for exploring surfaces of cells in vivo. Setting of surface cell focuses with advancement in immune response innovation have encouraged the generation of antibodies improved for non-obtrusive imaging.⁷¹ They have various applications, for example, radioimmunosciintigraphy, counter acting agent based and single-photon discharge processed tomography (SPECT or SPET) and positron emanation tomography (immuno-PET).⁷²

Epitope Mapping

Phage collections are helpful for designing counter acting agent epitopes, and show a huge number of peptides/proteins with novel arbitrary arrangements. Antibodies select the peptides as per the tendency of paratopes (their consolidating destinations) from the collection.⁷³

Immuno-Protective Epitope Mapping

Antibodies ensure an anchor across attacking microorganisms. These common antibodies kill poisons and instigate microbicidal effector capacities. Counter acting agent intervened recognizable proof of pathogens amid contamination is basic for uncovering immunoprotective reactions in the host.⁷⁴ B cell epitope (changeable locale of defensive antibodies in association with irresistible antigens) designing is imperative for the advancement of powerful immunizations in base of sero-diagnostics. This procedure recognizes defensive epitopes for immunization advancement and the evaluation of regular antibodies (slaughtered or weakened disease causing microbes).⁷⁵

B and T cell epitope adaptation is dictated by pepscan strategy, which has prompted the advancement of neutralizer remedial treatment, immunization outline, and acknowledgment of defensive counter acting agent reaction.⁷⁶ The system likewise targets disease causing microbes with different antimicrobials. Cases incorporate the V-formed Ab52 glycan epitope in the O-antigen of *Francisella tularensis*, the CR6261 peptidic epitope in flu infection H1N1, and the PG16 glycopeptidic epitope in the gp120 V1/V2 circle of HIV sort 1. Peptides are isolated by biopanning with antibodies from the sera of different human ailments, including serious intense respiratory disorder (SARS), human papillomavirus (HPV), and avian flu infections (AIV). In addition, peptide-based antigens are

additionally utilized for serological conclusion and advancement of immunizations.⁷⁷

Utilization of Antibody in Treatment of Infectious Diseases for Healthier Future

Antibodies are basic for resistance against irresistible maladies, and broadly utilized for counteractive action and cure of disease brought on by microscopic organisms, infection, and different irresistible operators to enhance general wellbeing. Emil von Behring was granted the main Nobel Prize in Physiology or Medicine in 1901 for his disclosure of serum treatment for diphtheria. This prompted the term immunizing agent and next named as "antikörper" deciphered "immunizer" by Paul Erlich in 1891.⁷⁸ The rise of recombinant advancements has upset the determination, refinement, and improvement of restorative antibodies and allowed the vital outline of neutralizer based components for specificity and differing qualities. Various hereditarily built mAbs have been utilized for the cure of different irresistible infections.

Ebola infection illness (EVD) is an extreme, frequently lethal, zoonotic contamination archived with latest boundless episode in the region of west Africa. It is brought about by an infection of the Filoviridae family (variety Ebolavirus). The illness is spread from human to human by means of connection with body liquids of the patients, the hatching time frame is 1–21 days and case casualty rates run from 30 to 90%.⁷⁹ A mAb known as ZMapp is made in the plant of tobacco *Nicotiana benthamiana* to cure EVD and to enhance general wellbeing. It contains a mixed drink of various mAbs (MB-003, c2G4, ZMab and c4G7) that work to turn away the transmission of the illness inside the body.⁸⁰ A current review examined the therapy of EVD patient with ZMapp, a buffy coat transmission from an Ebola survivor, and the wide range antiviral GS-5734. The first patient is a child recorded to have effectively get through EVD.⁸¹

Remedial antibodies have been produced to battle off a few irresistible malignancies. Malignancy is a gathering of maladies that include strange cell development and multiplication brought on by changes, or transformations, in the hereditary material of the phones. The cell enlargement or knots might be amiable or metastatic.⁸² Growth outpaces the invulnerable framework, stays away from discovery, or squares safe framework action. Along these lines, various restorative antibodies, for example, ganitumab, necitumumab, GRN1005, ramucirumab, BIIB 033, mapatumumab, cixutumumab MM-121, trebananib, carlumab and BQ880, have been examined for the effective therapy of human growths. The malignancies incorporate metastatic gastric adenocarcinoma, NSCLC, bosom, ovarian, peritoneal, mind metastasis prostate, fallopian tube, colorectal and pancreatic diseases, melanoma of the liver and eye, different myeloma and non-Hodgkin lymphoma.⁸³

Thus, designed antibodies have been utilized for the treatment of different sorts of joint inflammation. Joint pain



(from Greek word "joint") is an endless multifactorial illness in which resistant framework assaults and begins corrupting the body's joints. Helpful antibodies, for example, GSK319616, mavrilimumab, and adalimumab have been produced for the therapy of rheumatoid joint pain, adolescent idiopathic joint pain, psoriatic joint pain, and ankylosing spondylitis.⁸⁴

Remedial antibodies produced for the treatment of different irresistible illnesses incorporate prophylaxis, Bacillus anthracis, autoantibody-positive, angioedema, lupus, macular degeneration, safe thrombocytopenic purpura, hemophilia A, muscle misfortune, Alzheimer, psoriasis, and shortcoming, optic neuritis, pneumonic fibrosis, ulcerative colitis and asthma.

Anticipation of an illness is a perplexing procedure that include finding from a few perceptible manifestations and the decision of treatment in light of helpful viability. Antibodies, in view of their flawless specificity, and mAbs by and large display more prominent specificity. In this manner, they are utilized broadly in an assortment of examine configurations, in the conclusion and treatment of irresistible ailments. Additionally, they indicate quick distinguishing proof of new or uncommon irresistible operators that is a critical general wellbeing measure. In a matter of seconds, advancement of novel mAbs are observing and reduce the probabilities of pandemics and other ailment dangers forced on human wellbeing by common irresistible specialists.

CONCLUSION

In the former couple of decades, antibodies have been created by utilization of traditional strategies, for instance, hybridomas with basic applications in remedial treatments. In any case, more starting late, there have been movements in recombinant developments that have enhanced in the current period for the creation of immunoglobulins and their parts. Neutralizing immune response offers quick, fiscally economical, viable and capable biomedical instruments for the disclosure of high-enjoying peptides/proteins, examination of protein to protein affiliations, receptor authority, and epitope recognition proof. This able development is operated as a piece of an arrangement of systems to access differing request from an establishment of biotechnology and cell science. Further, it is practiced for the era of different sorts of outlined antibodies across any objective particle or particularly exceptional proportioned antigens. Immune response designing has wide range of natural, biotechnological, restorative, and counter acting agent applications for the improvement of different remedial treatments in different infection fields. Different unique and helpful medications have been created by in vitro screening and determination strategies in view of a few high throughput insusceptible effector capacities, designed antibodies, and high-proclivity immune response pieces. Taking everything into account, the review will help in knowing the noteworthiness of antibodies manufacture accession with broad utilization in sub-atomic, immunological, indicative, biomedical,

biotechnological fields, imaging, and seeking after a more beneficial future for people. Further, it is empowering in finding and cure of pollutions to upgrade human prosperity. Resistant reaction building has extensive variety of common, biotechnological, restorative, and neutralizer operations for the change of unique remedial treatments in different disease handling. This review has widely depicted advances in immunomodulation and neutralizer planning frameworks, assembled antibodies, demonstrate improvements in health and services of antibodies to human.

REFERENCES

1. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. *Nat. Rev. Immunol.* 8, 2008, 34-47.
2. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J. Clin. Oncol.* 21, 2003, 3940-3947.
3. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/V polymorphism. *Blood, Am. J. Hematol.* 110, 2007, 2561-2564.
4. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang H-M, Borucka E, Lurje G, Sherrod AE. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximab. *J. Clin. Oncol.* 25, 2007, 3712-3718.
5. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? *Nat. Clin. Pract. Oncol.* 3, 2006, 668-681.
6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. *Nat. Med.* 10, 2004, 909-915.
7. Jäger D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). In: *Target Discovery and Validation Reviews and Protocols*: Springer; 2007, 319-326.
8. Gunawardana CG, Diamandis EP. High throughput proteomic strategies for identifying tumour-associated antigens. *Cancer Lett.* 249, 2007, 110-119.
9. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. *Proc. Natl. Acad. Sci. U.S.A.* 104, 2007, 17494-17499.
10. Haanen J, Baars A, Gomez R, Weder P, Smits M, De Gruijl T, Von Blomberg B, Bloemena E, Scheper R, Van Ham S. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. *Cancer Immunol. Immunother.* 55, 2006, 451-458.
11. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. *Br. J. Pharmacol.* 157, 2009, 220-233.
12. Bradbury A, Velappan N, Verzillo V, Ovecka M, Chasteen L, Sblattero D, Marzari R, Lou J, Siegel R, Pavlik P. Antibodies in proteomics II: screening, high-throughput characterization and downstream applications. *Trends Biotechnol.* 21, 2003, 312-317.
13. Kontermann RE, Müller R. Intracellular and cell surface displayed single-chain diabodies. *J. Immunol. Methods.* 226, 1999, 179-188.
14. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. *Mol. Immunol.* 67, 2015, 95-106.



15. Attarwala H. Role of antibodies in cancer targeting. *J. Nat. Sci. Biol. Med.* 1, 2010, 53.
16. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. *Nat. Rev. Cancer.* 12, 2012, 278-287.
17. Vincent KJ, Zurini M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. *Biotechnol. J.* 7, 2012, 1444-1450.
18. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao S-W, Lencer WI, Pierce GF, Blumberg RS. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. *Crit. Rev. Biotechnol.* 35, 2015, 235-254.
19. Grevys A, Bern M, Foss S, Bratlie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT. Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. *J. Immunol.* 194, 2015, 5497-5508.
20. Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. In: *MAbs*. Taylor & Francis; 7, 2015, 494-504.
21. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. *Cell. Mol. Immunol.* 10, 2013, 230-252.
22. Berman D, Korman A, Peck R, Feltquate D, Lonberg N, Canetta R. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. *Pharmacol. Ther.* 148, 2015, 132-153.
23. Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I, Mahendra A, Charab W, Georgiou G, Roysam B. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. *Blood.* 124, 2014, 3241-3249.
24. Dicker M, Strasser R. Using glyco-engineering to produce therapeutic proteins. *Expert Opin. Biol. Ther.* 15, 2015, 1501-1516.
25. Dekkers G, Plomp R, Koeleman CA, Visser R, Von Horsten HH, Sandig V, Rispens T, Wuhler M, Vidarsson G. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. *Sci. Rep.* 6, 2016, 36964.
26. Cherf GM, Cochran JR. Applications of yeast surface display for protein engineering. In: *yeast surface display*: Springer; 2015:155-175.
27. Lei H, Jin S, Karlsson E, Schultz-Cherry S, Ye K. Yeast surface-displayed H5N1 avian influenza vaccines. *J. Immunol. Res.* 2016, 2016.
28. Li D, Gong R, Zheng J, Chen X, Dimitrov DS, Zhao Q. Engineered antibody CH2 domains binding to nucleolin: isolation, characterization and improvement of aggregation. *Biochem. Biophys. Res. Commun.* 485, 2017, 446-453.
29. Yuan J, Zhang C, Fang S, Zhuang Z, Ling S, Wang S. A monoclonal antibody against F1-F0 ATP synthase beta subunit. *Hybridoma.* 31, 2012, 352-357.
30. Mee-Jung H, Lee SH. An efficient bacterial surface display system based on a novel outer membrane anchoring element from the *Escherichia coli* protein YiaT. *FEMS Microbiol. Lett.* 362, 2015, 1-7.
31. Ramanan R, Kim B-H, Cho D-H, Oh H-M, Kim H-S. Algae-bacteria interactions: evolution, ecology and emerging applications. *Biotechnol. Adv.* 34, 2016, 14-29.
32. Kasi D, Catherine C, Lee SW, Lee KH, Kim YJ, Ro Lee M, Ju JW, Kim DM. Cell-free translational screening of an expression sequence tag library of *Clonorchis sinensis* for novel antigen discovery. *Biotechnol. Prog.* 33, 2017, 832-837.
33. Zhao XL, Tian LF, Zhang SJ, Li JM, Feng H, Wang LM, Wang S, Wang J, Wang T, Chen WQ. Novel Human Three-Domain Antibody Fragments Against sTNF α as Well as tm TNF α with High Affinity Generated by the Combination of Ribosome Display and *E. coli* Expression System. *Scand. J. Immunol.* 83, 2016, 267-278.
34. Montero MF, Aristizábal M, Reina GG. Isolation of high-lipid content strains of the marine microalga *Tetraselmis suecica* for biodiesel production by flow cytometry and single-cell sorting. *J. Appl. Phycol.* 23, 2011, 1053-1057.
35. Sundar S, Kumar Prajapati V. Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. *Curr. Med. Chem.* 19, 2012, 3196-3202.
36. Alonso N, Guillen R, Chambers JW, Leng F. A rapid and sensitive high-throughput screening method to identify compounds targeting protein-nucleic acids interactions. *Nucleic Acids Res.* 43, 2015, e52-e52.
37. Grange R, Thompson J, Lambert D. Radioimmunoassay, enzyme and non-enzyme-based immunoassays. *Br. J. Anaesth.* 112, 2014, 213-216.
38. Thiha A, Ibrahim F. A colorimetric enzyme-linked immunosorbent assay (ELISA) detection platform for a point-of-care dengue detection system on a lab-on-compact-disc. *Sensors.* 15, 2015, 11431-11441.
39. Brasino M, Lee JH, Cha JN. Creating highly amplified enzyme-linked immunosorbent assay signals from genetically engineered bacteriophage. *Anal. Biochem.* 470, 2015, 7-13.
40. Peng D, Yang B, Pan Y, Wang Y, Chen D, Liu Z, Yang W, Tao Y, Yuan Z. Development and validation of a sensitive monoclonal antibody-based indirect competitive enzyme-linked immunosorbent assay for the determination of the aflatoxin M1 levels in milk. *Toxicon.* 113, 2016, 18-24.
41. Dupont-Deshorgue A, Oudart J, Brassart B, Deslee G, Perotin J, Diebold M, Monboisse J, Ramont L, Brassart-Pasco S. A competitive enzyme-linked immunosorbent assay for quantification of tetrastatin in body fluids and tumor extracts. *Anal. Biochem.* 482, 2015, 16-21.
42. Qu H, Wang X, Qu B, Kong H, Zhang Y, Shan W, Cheng J, Wang Q, Zhao Y. Sandwich enzyme-linked immunosorbent assay for naringin. *Anal. Chim. Acta.* 903, 2016, 149-155.
43. Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. *PLoS One.* 11, 2016, e0154285.
44. Ness TL, Robinson RL, Mojadedi W, Peavy L, Weiland MH. A streamlined Western blot exercise: An efficient and greener approach in the laboratory classroom. *Biochem. Mol. Biol. Educ.* 43, 2015, 358-365.
45. Lewis CW, Taylor RG, Golsteyn RM. Measurement of Cdk1/Cyclin B kinase activity by specific antibodies and western blotting. In: *Cell Cycle Oscillators*: Springer; 2016:337-348.
46. Arya P, Ponmariappan S, Singh L, Kumar O. Development of ELISA based detection system for lethal toxin of *Clostridium sordellii*. *Indian J. Med. Res.* 137, 2013, 1180.
47. Skinner C, Patfield S, Stanker L, He X. Development of monoclonal antibodies and immunoassays for sensitive and specific detection of Shiga toxin Stx2f. *PLoS One.* 8, 2013, e76563.
48. Yu H, Liu H, Yan Y, Duan Z, Wang X. Detection and identification of huwentoxin-IV interacting proteins by biotin-avidin chemistry combined with mass spectrometry. *J. Venom Anim. Toxins Incl. Trop. Dis.* 20, 2014, 18.
49. Wang R, Zhong Y, Gu X, Yuan J, Saeed AF, Wang S. The pathogenesis, detection, and prevention of *Vibrio parahaemolyticus*. *Front. Microbiol.* 6, 2015, 144.
50. Emmerich CH, Cohen P. Optimising methods for the preservation, capture and identification of ubiquitin chains and ubiquitylated proteins by immunoblotting. *Biochem. Biophys. Res. Commun.* 466, 2015, 1-14.
51. Subramanian S, Mahadevan A, Satishchandra P, Shankar SK. Development of a dot blot assay with antibodies to recombinant "core" 14-3-3 protein: Evaluation of its usefulness in diagnosis of Creutzfeldt-Jakob disease. *Ann. Indian Acad. Neurol.* 19, 2016, 205.
52. Zhu S, Schuerch C, Hunt J. Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. *Arch. Pathol. Lab. Med.* 139, 2015, 55-66.

53. Diorio C, Furrer D, Michaud A, Laberge S, Popa I, Jacob S, Provencher L, Hogue J-C. Validation of EP1 antibody clone for estrogen receptor immunohistochemistry for breast cancer. *Anticancer Res.* 36, 2016, 435-437.
54. Guo H, Li H, Wang B, Ding W, Ling L, Yang M, Niu J, Gu Y. Protective effects of glucagon-like peptide-1 analog on renal tubular injury in mice on high-fat diet. *Cell Physiol. Biochem.* 41, 2017, 1113-1124.
55. Dana P, Kariya R, Vaeteewoottacharn K, Sawanyawisuth K, Seubwai W, Matsuda K, Okada S, Wongkham S. Upregulation of CD147 promotes metastasis of cholangiocarcinoma by modulating the epithelial-to-mesenchymal transitional process. *Oncol. Res.* 25, 2017, 1047-1059.
56. Berguido FJ, Bodjo SC, Loitsch A, Diallo A. Specific detection of peste des petits ruminants virus antibodies in sheep and goat sera by the luciferase immunoprecipitation system. *J. Virol. Methods.* 227, 2016, 40-46.
57. Cohen JI, Ali MA, Bayat A, Steinberg SP, Park H, Gershon AA, Burbelo PD. Detection of antibodies to varicella-zoster virus in recipients of the varicella vaccine by using a luciferase immunoprecipitation system assay. *Clin. Vaccine Immunol.* 21, 2014, 1288-1291.
58. Ustinova J, Zusinaite E, Utt M, Metsküla K, Reimand K, Huchaiah V, Merits A, Uibo R. Development of a luciferase-based system for the detection of ZnT8 autoantibodies. *J. Immunol. Methods.* 405, 2014, 67-73.
59. Hou W, Yang L, He D, Zheng J, Xu L, Liu J, Liu Y, Zhao H, Ye X, Cheng T. Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay. *J. Virol. Methods.* 215, 2015, 56-60.
60. Li T, Lin H, Yu L, Xue M, Ge S, Zhao Q, Zhang J, Xia N. Development of an enzyme-linked immunospot assay for determination of rotavirus infectivity. *J. Virol. Methods.* 209, 2014, 7-14.
61. Chang DY, Lee J, Choi SW, Lee HJ, Kang H, Yeo SC, Joo YH, Cho HJ, Jeon SY, Kim RB. Interleukin-4 enzyme-linked immunospot assay may be useful for diagnosing sensitization to house dust mite. In: *Int. Forum Allergy Rhinol. Wiley Online Library*; 6, 2016, 1007-1012.
62. Pang C, Wu Y, Wan C, Shen K, Hu Y, Yang T, Shen Y, Wen F. Accuracy of the bronchoalveolar lavage enzyme-linked immunospot assay for the diagnosis of pulmonary tuberculosis: a meta-analysis. *Medicine.* 95, 2016.
63. Adilistya T, Astrawinata DA, Nasir UZ. Use of pleural fluid interferon-gamma enzyme-linked immunospot assay in the diagnosis of pleural tuberculosis. *Acta Med. Indones.* 48, 2016, 41.
64. Neshar L, Shah DP, Ariza-Heredia EJ, Azzi JM, Siddiqui HK, Ghantaji SS, Marsh LY, Michailidis L, Makedonas G, Rezvani K. Utility of the Enzyme-Linked Immunospot Interferon- γ -Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. *J. Infect. Dis.* 213, 2016, 1701-1707.
65. Hansson J, Yasuga H, Haraldsson T, Van der Wijngaart W. Synthetic microfluidic paper: high surface area and high porosity polymer micropillar arrays. *Lab. Chip.* 16, 2016, 298-304.
66. Yu A, Shang J, Cheng F, Paik BA, Kaplan JM, Andrade RB, Ratner DM. Biofunctional paper via the covalent modification of cellulose. *Langmuir.* 28, 2012, 11265-11273.
67. Gui C, Wang K, Li C, Dai X, Cui D. A CCD-based reader combined with CdS quantum dot-labeled lateral flow strips for ultrasensitive quantitative detection of CagA. *Nanoscale Res. Lett.* 9, 2014, 1-8.
68. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: An updated review. *Int. J. Pharm. Investig.* 2, 2012, 2.
69. Fitting J, Blume T, ten Haaf A, Blau W, Gattenlöhner S, Tur MK, Barth S. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. In: *MAbs. Vol 7: Taylor & Francis*; 2015:390-402.
70. Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. *BBA Clin.* 3, 2015, 280-288.
71. Manning HC, Lander A, McKinley E, Mutic NJ. Accelerating the development of novel molecular imaging probes: a role for high-throughput screening. *J. Nucl. Med.* 49, 2008, 1401-1404.
72. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. *J. Clin. Oncol.* 30, 2012, 3884.
73. Forsström B, Axnäs BB, Stengele K-P, Bühler J, Albert TJ, Richmond TA, Hu FJ, Nilsson P, Hudson EP, Rockberg J. Proteome-wide epitope mapping of antibodies using ultra-dense peptide arrays. *Mol. Cell Proteomics.* 13, 2014, 1585-1597.
74. Sharon J, Rynkiewicz MJ, Lu Z, Yang CY. Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. *Immunology.* 142, 2014, 1-23.
75. Malito E, Carfi A, Bottomley MJ. Protein crystallography in vaccine research and development. *Int. J. Mol. Sci.* 16, 2015, 13106-13140.
76. Ahmad TA, Eweida AE, Sheweita SA. B-cell epitope mapping for the design of vaccines and effective diagnostics. *Trials Vaccinol.* 5, 2016, 71-83.
77. Wu C-H, Liu I-J, Lu R-M, Wu H-C. Advancement and applications of peptide phage display technology in biomedical science. *J. Biomed. Sci.* 23, 2016, 1-14.
78. Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. *Curr. Opin. HIV AIDS.* 10, 2015, 129.
79. Beeching NJ, Fenech M, Houlihan CF. Ebola virus disease. *BMJ.* 349, 2014, g7348.
80. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. *Nature.* 514, 2014, 47-53.
81. Dörnemann J, Burzio C, Ronsse A, Sprecher A, De Clerck H, Van Herp M, Kolié M-C, Yosifiva V, Caluwaerts S, McElroy AK. First newborn baby to receive experimental therapies survives Ebola virus disease. *J. Infect. Dis.* 215, 2017, 171-174.
82. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. *Biochim. Biophys. Acta.* 1805, 2010, 105-117.
83. Nixon AE, Sexton DJ, Ladner RC. Drugs derived from phage display: from candidate identification to clinical practice. In: *MAbs. Taylor & Francis*; 6, 2014, 73-85.
84. Dantas-Barbosa C, de Macedo Brigido M, Maranhao AQ. Antibody phage display libraries: contributions to oncology. *Int. J. Mol. Sci.* 13, 2012, 5420-5440.

Source of Support: None declared.

Conflict of Interest: None declared.

For any question relates to this article, please reach us at: editor@globalresearchonline.net

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com

